NASDAQ: CYTH - Cyclo Therapeutics, Inc.

半年間の収益性: -8.67%
配当利回り: 0.00%
セクタ: Healthcare

プロモーションスケジュール Cyclo Therapeutics, Inc.

詳細なスケジュール 簡易グラフ
Financial Markets by TradingView

会社について Cyclo Therapeutics, Inc.

Cyclo Therapeutics, Inc., a clinical stage biotechnology company, develops cyclodextrin-based products for the treatment of neurodegenerative diseases. Its lead drug candidate is Trappsol Cyclo, an orphan drug, which is Phase III clinical trials for the treatment of Niemann-Pick Type C disease. The company also develops Trappsol Cyclo that is in Phase IIb clinical trials for the treatment of Alzheimer's disease. In addition, it sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs.

さらに詳しく
The company was formerly known as CTD Holdings, Inc. and changed its name to Cyclo Therapeutics, Inc. in September 2019. Cyclo Therapeutics, Inc. was incorporated in 1990 and is based in Gainesville, Florida.
比較リストに追加
ウォッチリストに追加
ポートフォリオに追加
価格通知を追加

IPO date 2011-02-23
ISIN US23254X2018
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://cyclotherapeutics.com
Цена ао 0.7206
1日あたりの価格変動: 0% (0.7206)
週ごとの価格変動: +2.94% (0.7)
月ごとの料金変更: -6.29% (0.769)
3ヶ月間の価格変動: +20.5% (0.598)
半年間の価格変動: -8.67% (0.789)
年間の価格変動: -48.16% (1.39)
3年間の価格推移: -74.72% (2.85)
5年間の価格推移: +325.13% (0.1695)
年初からの価格変動: +22.14% (0.59)
すべてのパラメータ

過小評価

名前 意味 学年
P/S 9.13 1
P/BV 2.06 7
P/E 0 0
EV/EBITDA -0.0803 0
合計: 4.75

効率

名前 意味 学年
ROA, % -151.4 0
ROE, % -421.64 0
合計: 0

配当金

名前 意味 学年
Div yield, % 0 0
DSI 0 0
合計: 0

義務

名前 意味 学年
Debt/EBITDA -0.0516 10
合計: 10

成長の衝動

名前 意味 学年
収益性 Revenue, % 19.2 3
収益性 Ebitda, % 122.56 10
収益性 EPS, % -77.99 0
合計: 6.4
さらに詳しく

機関 音量 共有, %
Founders Fund V Management, LLC 480708 1.67
Vanguard Group Inc 355223 1.24
Geode Capital Management, LLC 152077 0.53
Founders Fund VI Management, LLC 110023 0.38
Citadel Advisors Llc 54018 0.19
Blackrock Inc. 48444 0.17
State Street Corporation 39525 0.14
Wealth Enhancement Advisory Services, LLC 18513 0.06
Northern Trust Corporation 17453 0.06
XTX Topco Ltd 10696 0.04

ETF共有, %年間の利益率, %配当金, %
iShares Micro-Cap ETF 0.00344 17.09 1.54048
017.091.54



スーパーバイザー 役職 支払い 生年
Mr. N. Scott Fine CEO & Director 569.92k 1957 (68 年)
Mr. C. E Strattan Founder & Director N/A 1946 (79 年)
Mr. Joshua M. Fine CFO & Secretary 421.17k 1982 (43 年)
Mr. Michael Eric Lisjak Senior VP of Business Development & Chief Regulatory Officer 430.4k 1974 (51 年)
Dr. Jeffrey L. Tate Ph.D. COO, Chief Quality Officer & Director 255.14k 1958 (67 年)
Dr. Karen Mullen FFPM Interim Chief Medical Officer N/A
Ms. Lori McKenna Global Head of Patient Advocacy N/A

住所: United States, Gainesville. FL, 6714 NW 16th Street - Googleマップで開く, Yandexマップを開く
Webサイト: https://cyclotherapeutics.com